Regulatory Unwrapped: Breaking down the FCA’s NFM framework
Join us for a deeper dive into the biggest regulatory trends and challenges firms are facing as we chat with experts and understand how organizations can keep pace with fast-paced compliance changes.
Regulatory Wrap episode 86: FCA NFM rules – Is your firm ready?
In Regulatory Wrap for the week to July 31, Rob Mason covers the FCA’s expanded NFM rules, which go into effect on September 1, 2026.
Checklist: 10 steps to help you meet September’s NFM-rule deadline
With the FCA’s September 2026 NFM deadline looming, we’ve created a 10-step checklist to help FSMA-authorized firms prepare - covering policy, HR, surveillance, training, and regulatory notification requirements
What the DOJ’s 2026 Corporate Enforcement Policy update means for compliance teams
Learn more about the Department of Justice's 2026 update to its Corporate Enforcement Policy, and how AI-enabled communications monitoring can help you stay ahead of regulatory enforcement by detecting and flagging misconduct before a whistleblower does.
Non-Financial Misconduct Rules Extending to SMCR Firms: An essential guide
With the FCA set to expand its non-financial misconduct (NFM) rules to 37,000 additional firms, we've put together an essential guide to what the changes mean, and how firms can prepare for them.
Regulatory Wrap episode 76: FCA NFM final rules
In Regulatory Wrap for the week to January 16, Jay Hampshire unpacks the FCA’s final guide on non-financial misconduct.
What advice does the DOJ have for pharma compliance teams?
The DOJ assistant attorney general emphasized proactive self-disclosure and hinted at how pharmaceuticals can best prepare for new trends in enforcement.
Regulatory Wrap episode 74: The FCA knows what you did last summer
In Regulatory Wrap for the week to October 31, Jay Hampshire breaks down a speech from the FCA, which reinforces its “do the right thing” motto.
Regulatory Wrap episode 72: FCA’s call to action on financial crime
In Regulatory Wrap for the week to October 10, Jay Hampshire summarizes the FCA’s recent speech encouraging collaboration to fight financial crime.
Personal devices in crisis? Risks vs. rewards of BYOD policies in pharmaceuticals
Pharmaceutical companies face a tough choice between enabling BYOD or issuing corporate devices. Understand the risks, rewards, and compliance factors of both.